A systematic review and economic model of the effectiveness and ...

78
Clinical effectiveness
dermatitis, pruritus, rash and sweating. Prostatitis
in men and menstrual disturbances in women
have also been observed. Some patients have
suffered from cold extremities, although less
commonly. Behavioural side-effects include sleep
disturbances, depression, anxiety and sexual
dysfunction.
IR-MPH versus ER-MPH
Primary studies
Of the studies that evaluated IR-MPH compared
with ER-MPH, one study reported a significantly
higher incidence of headache in the extendedrelease
treatment group. 97
MPH versus DEX
Primary studies
Amongst studies comparing IR-MPH with IR-DEX
(of any respective dosage, with or without nondrug
intervention), no significant differences were
detected between treatment groups with regard to
reported adverse events. 50,51
No significant differences were detected in the
incidence of insomnia in the one study comparing
ER-DEX combined with a non-drug intervention
with IR-MPH (medium dose) combined with a
non-drug intervention. No further data were
reported. 78
Similarly, no significant differences were found in
the incidence of insomnia between treatment
phases in the one study comparing ER-MPH
combined with a non-drug intervention with ER-
DEX combined with a non-drug intervention. No
further data were reported. 78
MPH versus ATX
Primary studies
The study comparing MPH (high dose) with ATX
(high dose) did not detect significant differences
in adverse events between treatment groups. 70
However, the study comparing an extendedrelease
form of MPH (medium dose) with ATX
(low/medium dose) found that participants
assigned to ER-MPH suffered from reduced
appetite and insomnia to a significantly greater
extent. No differences were detected in the
incidence of headache or stomach ache between
treatment groups. 99
ATX versus DEX
Primary studies
No studies compared ATX versus DEX.